Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585143 · ClinicalTrials.gov registry record · Phase 1
Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly
A Phase 1 study of Dyslipidemia, Renal Insufficiency, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 6
- Study locations
NCT00585143: Completed Phase 1 study of Dyslipidemia, Renal Insufficiency, sponsored by AstraZeneca.
NCT00585143 is a Phase 1 study of Dyslipidemia, Renal Insufficiency that has completed, run by AstraZeneca. The registered enrollment target is 37 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (38% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00585143, a Phase 1 study of Dyslipidemia, Renal Insufficiency, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 6
- Study locations
Study Summary
Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly
Conditions Studied
Interventions
- DRUG Rosuvastatin
- DRUG ABT-335
Study Locations (6)
Florida
- Site Reference ID/Investigator# 6610 - Gainesville
- Site Reference ID/Investigator# 6738 - Miami
Minnesota
- Site Reference ID/Investigator# 7723 - Minneapolis
Tennessee
- Site Reference ID/Investigator# 7319 - Knoxville
Texas
- Site Reference ID/Investigator# 6928 - San Antonio
Virginia
- Site Reference ID/Investigator# 8280 - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
What the finished NCT00585143 record still lists
NCT00585143 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (38% lower).
The record links to 1 condition, with Dyslipidemia, Renal Insufficiency appearing as the primary indexed condition, and to 2 interventions - of which Rosuvastatin is the first listed.
NCT00585143 lists 6 locations in 5 states (Florida, Minnesota, Tennessee).
Frequently Asked Questions
What is clinical trial NCT00585143 about?
NCT00585143 is a clinical study titled "Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly". Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly
What is the current status of trial NCT00585143?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2008-01. Estimated completion is 2008-10.
What conditions does trial NCT00585143 study?
This clinical trial studies the following conditions: Dyslipidemia, Renal Insufficiency.
What interventions are being tested in trial NCT00585143?
The interventions under investigation include: Rosuvastatin (DRUG), ABT-335 (DRUG).
Who is sponsoring clinical trial NCT00585143?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00585143 being conducted?
This trial has 6 study locations across Florida, Minnesota, Tennessee, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00585143's enrollment target sits among peer trials
37 1204th of 2000 higher than 791 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia